Co-Authors
This is a "connection" page, showing publications co-authored by Luigi Naldi and Simone Cazzaniga.
Connection Strength
2.176
-
More on Covid-19 in Immune-Mediated Inflammatory Diseases. N Engl J Med. 2020 08 20; 383(8):795-796.
Score: 0.892
-
Assessing the Risk and Outcome of COVID-19 in Patients with Psoriasis or Psoriatic Arthritis on Biologic Treatment: A Critical Appraisal of the Quality of the Published Evidence. J Invest Dermatol. 2022 02; 142(2):355-363.e7.
Score: 0.240
-
Preference for Telemedicine Versus In-Person Visit Among Patients with Psoriasis Receiving Biological Drugs. Dermatol Ther (Heidelb). 2021 Aug; 11(4):1333-1343.
Score: 0.238
-
Time of Onset of Selected Skin Lesions Associated with COVID-19: A Systematic Review. Dermatol Ther (Heidelb). 2021 Jun; 11(3):695-705.
Score: 0.234
-
Is SARS-CoV-2 screening test indicated for psoriasis patients candidate to biologic therapy? J Eur Acad Dermatol Venereol. 2021 Jun; 35(6):e355-e357.
Score: 0.233
-
Lack of Evidence for an Increased Risk of Severe COVID-19 in Psoriasis Patients on Biologics: A Cohort Study from Northeast Italy. Am J Clin Dermatol. 2020 10; 21(5):749-751.
Score: 0.226
-
Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experience. J Allergy Clin Immunol. 2021 Feb; 147(2):558-560.e1.
Score: 0.057
-
The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience. Br J Dermatol. 2020 08; 183(2):373-374.
Score: 0.055